Myeloid-Derived Suppressor Cells Expressing Myeloperoxidase Directly Inhibit Adaptive Immune Cells Limiting Immunotherapy in Melanoma
Abstract
A recent breakthrough in treating melanoma patients is the use of immune checkpoint therapy (ICT). Unfortunately, the majority of patients do not respond to ICT. Complicating matters, is that as cancer develops, it can re-program immune cells to work in favor of tumor growth. One such population of cells are myeloid-derived suppressor cells (MDSCs). MDSCs dampen the immune system from recognizing cancer and decrease ICT treatment response. Preliminary data suggests that the enzyme myeloperoxidase is overexpressed in MDSCs. We hypothesize that by limiting the function of myeloperoxidase, we limit the effects of MDSCs to enable successful ICT response in melanoma.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2023
- Accession Number
- AD1210822
Entities
People
- Tracy Liu
Organizations
- West Virginia University